De-Risking Immunotherapy Targets with Next-Gen HLA Discovery Platforms
Dr. Rico Buchli and the HLA Protein Technologies team provide answers to questions from their webinar on next-generation soluble HLA peptide discovery platforms to strengthen early immunotherapy R&D.
De-Risking Immunotherapy Targets with Next-Gen HLA Discovery Platforms
In this webinar, Rico Buchli, PhD, shares how next-generation soluble HLA peptide discovery platforms can strengthen early immunotherapy R&D - from target identification and confirmation to receptor/drug validation and translational decision-making.
Is DNA Vaccination the Future of Type 1 Diabetes Prevention and Management?
Given the fact that type 1 diabetes can vary considerably between individuals, a precision medicine-based therapeutic approach could revolutionize clinical care. Earlier this year, Postigo-Fernandez et al. evaluated a precision medicine approach to DNA vaccination in a mouse model of type 1 diabetes, which we review in this blog post.
